|
Published by: SMI Publishing, Ltd
Published: Jan. 30, 2006
Table of Contents
- Day 1
- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Dr Søren Bregenholt, Director, Project Management, Symphogen A/S.
- 9.10 OVERVIEW OF THE THERAPEUTIC ANTIBODIES MARKET
- The dynamic antibody industry
- Market overview
- Exploring the European therapeutic antibodies market
- Improving the efficacy of mab therapeutics likely to benefit growth
- Technology trends
- The road ahead
- Dr Mark Belsey, Analyst, Datamonitor.
- 9.50 ASSESSING AND GENERATING ANTIBODY IP
- Learn how to protect antibodies through patenting and how to assess third party antibody patents
- IP landscape for antibody phage display
- Comparison of USPTO and EPO approaches to antibody claims
- Strategies for protecting antibodies
- Approaches for assessing third party antibody patents
- Dr Diane Wilcock, Vice President, Intellectual Property, Cambridge Antibody Technology.
- 10.30 Morning Coffee
- 11.00 PRECLINICAL DEVELOPMENT
- The development of antibodies
- HuCAL ® Human Combatorial Antibody Library
- Therapeutic antibodies in development
- MOR antibody development
- Collaborative development programmes
- Dr Robert Friesen, Director, Preclinical Development, Morphosys A G.
- 11.40 SYNTHETIC THERAPEUTIC ANTIBODIES
- Application of structure- based design to antibody development
- High affinity antibodies dervied from synthetic repertoires
- Structural and functional analysis of antigen recognition
- Highly optimised synthetic libraries with limited amino acid diverisities
- Implications for antibody engineering and therapeutic antibodies
- Dr Frederic Fellouse, Research Scientist, Genentech.
- 12.20 Networking Lunch
- 1.50 ANTIBODY PHAGE DISPLAY
- Novel therapeutic human antibody leads using phage display technology
- Construction and use of Dyax novel phage and phagemid human antibody libraries
- Novel antibody diversity combining careful synthetic design with natural human human donor diversity
- Automated controlled phage display selcetion methods on purified protein targets, peptides and cells
- High throughput screening methods to identify antibody leads
- Case study: Tie-1 targeted inhibitor of tumour growth
- Mr Rene Hoet, Senior Director, Discovery Research, Dyax.
- 2.30 ANTIBODY ENGINEERING
- Assessment of antibody effector function in whole blood
- Can antibody effector function be reliably measured in whole blood by flow cytometry?
- Can models be established that predicts clinical observations?
- Can this data be used to delineate mechanism of action?
- Can such assays demonstrate on-target effects?
- Dr John Ferbas, Principal Scientist, Amgen.
- 3.10 Afternoon Tea
- 3.40 PRACTICAL MEASURES FOR REDUCING IMMUNOGENICITY
- Factors that influence immunogenicity of therapeutic proteins
- Identification of T cell epitopes
- Determining relative immunogenicity of proteins
- Modification of T cell epitopes to reduce immunogencity
- Dr Dave Estell, Vice President, Technology Research, Genencor International.
- 4.20 IMMUNOGENICITY AND REGULATORY STANDARDS
- Identifying the route from CBER to CDER
- Clinical development aspects
- Identification and optimisation of immunogenic epitopes
- Regulatory authorities - a long process to the final stage
- The movement of antibody products from CBER to CDER
- Dr Leon Hooftman, CMO, chroma therapeutics.
- 5.00 Chairman’s Closing Remarks and Close of Day One
- Day 2
- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Dr Hans de Haard, Scientific Director, Ablynx.
- 9.10 DEVELOPMENT OF THERAPEUTIC ANTIBODIES TO GENOMIC DERIVED TARGETS
- Dr Vivian Albert, Vice President, Development Sciences & Research, Human Genome Sciences.
- 9.50 NEW INNOVATIONS IN THE THERAPEUTIC ANTIBODIES MARKET
- In vitro evolution of therapeutic antibodies using ribosome display
- CAT-354 for treatment of severe asthma, an affinity-matured human anti-IL-13 antibody
- Identification of mutation hot-spots and their synergistic contribution to antibody potency improvements
- Exploring antibody-antigen interaction
- optimisation of biophysical characteristics like stability or solubility
- Application to other therapeutic proteins
- Dr Patrick Dufner, Research Scientist, Cambridge Antibody Technology.
- 10.30 Morning Coffee
- 11.00 RITUXIMAB - CHANGING THE LANDSCAPE OF NHL/CLL TREATMENT
- Non Hodgkin's Lymphoma and CLL
- Brief review of NHL/CLL disease area and potential targets for antibody treatment
- Treatment algorithms over the last 25 years in NHL/CLL
- Structure and mode of action of Rituximab
- Key data generated and published in the last few years
- Impact of Rituximab on treatment guidelines and habits of NHL/CLL
- Lessons we learnt so far to further improve antibody treatment in NHL/CLL
- Elisabeth Wassner, Clinical Scientist, roche.
- 11.40 PATIENT SPECIFIC ANTIBODY THEREAPY FOR NON-HODGKINS LYMPHOMA
- Alternative to phage display
- Patient specific drug development
- Rapid identification of recombinant antibodies using microarray displays
- Rapid formulation of recombinant antibodies into therapeutic molecules
- Functional cell-based screening of antibody libraries using microarray displays
- Dr Dana Ault-Riche, CEO, Pointilliste.
- 12.20 Networking Lunch
- 1.50 INFECTIOUS DISEASES
- Prophylaxis and treatment of infectious diseases with antibodies
- Isolation of antibody specificities
- Characterisation of antigens - epitopes and affinities
- In vitro functional performance of teh antibodies
- In vivo studies in small animals
- Mr John de Kruif, Director, Antibody Research and Development, Crucell.
- 2.30 HOW CAMBRIDGE ANTIBODY TECHNOLOGY DELIVERS LEADS
- Overview of selection therapies
- Screening for function
- IgG conversion
- Dr Gerald Beste, Team Leader, Lead Discovery, Cambridge Antibody Technology.
- 3.10 Afternoon Tea
- 3.40 USING NANOBODIES AS NEW THERAPEUTIC ENTITIES
- In vitro and in vivo efficacy data
- The unique properties of Nanobodies and their potential as breakthrough therapeutics
- Nanobodies against TNFa for the prevention of rheumatoid arthritis and inflammatory bowel disease
- Anti Von Willebrand factor Nanobodies for prevention of arterial thrombosis
- Nanobodies against CEA and EGFR for the treatment of cancer
- Dr Hans de Haard, Scientific Director, Ablynx.
- 4.20 DEVELOPMENT OF RECOMBINANT HUMAN POLYCLONAL ANTIBODY THERAPEUTICS
- Innovative technology for cloning cognate human antibodies
- Expression of recombinant human polyclonal antibodies
- Regulatory strategy for obtaining approval of recombinant polyclonal antibody pharmaceuticals
- Development of Sym001; anti-RhD polyclonal antibodies for treatment of ITP and HDN
- Dr Søren Bregenholt, Director, Project Management, Symphogen A/S.
- 5.00 Chairman’s Closing Remarks and Close of Conference
AbstractSMi’s 6th Conference on ‘Therapeutic Antibodies’ will provide a forum for leading industry experts from major pharmaceutical companies to discuss and evaluate the latest challenges and problems facing the therapeutic antibodies market.
It is predicted that therapeutic antibodies will form one of the fastest growing segments of the pharmaceutical market, and is expected to be worth more than $86 billion dollars by the year 2025. The success of current marketed products has led to an explosion in antibody development, with hundreds of programmes currently in the pipeline.
This conference will discuss the latest developments and outline the most recent trends and innovations in the therapeutic antibodies market. Particular focus will be given to the latest regulatory standards and intellectual property, which affect developments in this market.
SMi’s Therapeutic Antibodies conference is a must attend event and will provide an excellent opportunity to network, enhance your company’s profile and keep you up-to-date on the latest issues in the market.
An unique opportunity to learn from leading industry experts, including:
- Dr Rene Hoet, Director, Research & Technology, Dyax
- Dr John de Kruif, Director, Antibody Research & Development, Crucell
- Dr Dave Estell, Vice President, Technology, Genencor
- Dr Robert Friesen, Director, Preclinical Development, MorphoSys
- Dr Diane Wilcock, Vice President, Intellectual Property, Cambridge Antibody Technology
- Dr Leon Hooftman, Chief Medical Officer, Chroma Therapeutics
- Dr Hans de Haard, Scientific Director, Ablynx
- Elisabeth Wassner, Clinical Scientist, F. Hoffmann-La Roche
- Dr Frederic Fellouse, Senior Research Scientist, Genentech
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
